{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yin J"],"funding":["Science and Technology Bureau of Kaifeng","Science and Technology Department of Henan Province"],"pagination":["2119763"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9746490"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["18(6)"],"pubmed_abstract":["Patients with solid cancer have an increased risk of severe coronavirus disease 2019 (COVID-19) and associated mortality than the general population. This meta-analysis aimed to investigate the currently available evidence about the efficacy of COVID-19 vaccines in patients with solid cancer. We included prospective studies comparing the immunogenicity and efficacy of COVID-19 vaccines between patients with solid cancer and healthy individuals. Relative risks of seroconversion after the first and second dose of a COVID-19 vaccine were separately pooled with the use of random effects meta-analysis. Thirty studies with 11,245 subjects met the inclusion criteria. After first vaccine dose, the pooled RR of seroconversion in patients with solid cancer <i>vs</i> healthy individuals was 0.54 (95% CI 0.38-0.78, <i>I</i><sup><i>2</i></sup> = 94%). After a second dose, the pooled RR of seroconversion in patients with solid cancer <i>vs</i> healthy controls was 0.87 (0.86-0.88, <i>I</i><sup><i>2</i></sup> = 87%). Our review suggests that, compared with healthy individuals, COVID-19 vaccines show favorable immunogenicity and efficacy in patients with solid cancer. A second dose is associated with significantly improved seroconversion, although it is slightly lower in patients with solid cancer compared with healthy individuals."],"journal":["Human vaccines & immunotherapeutics"],"pubmed_title":["Seroconversion rate after COVID-19 vaccination in patients with solid cancer: A systematic review and meta-analysis."],"pmcid":["PMC9746490"],"funding_grant_id":["112102310306","119"],"pubmed_authors":["Li Y","Wang C","Zhang X","Chen Y","Yin J"],"additional_accession":[]},"is_claimable":false,"name":"Seroconversion rate after COVID-19 vaccination in patients with solid cancer: A systematic review and meta-analysis.","description":"Patients with solid cancer have an increased risk of severe coronavirus disease 2019 (COVID-19) and associated mortality than the general population. This meta-analysis aimed to investigate the currently available evidence about the efficacy of COVID-19 vaccines in patients with solid cancer. We included prospective studies comparing the immunogenicity and efficacy of COVID-19 vaccines between patients with solid cancer and healthy individuals. Relative risks of seroconversion after the first and second dose of a COVID-19 vaccine were separately pooled with the use of random effects meta-analysis. Thirty studies with 11,245 subjects met the inclusion criteria. After first vaccine dose, the pooled RR of seroconversion in patients with solid cancer <i>vs</i> healthy individuals was 0.54 (95% CI 0.38-0.78, <i>I</i><sup><i>2</i></sup> = 94%). After a second dose, the pooled RR of seroconversion in patients with solid cancer <i>vs</i> healthy controls was 0.87 (0.86-0.88, <i>I</i><sup><i>2</i></sup> = 87%). Our review suggests that, compared with healthy individuals, COVID-19 vaccines show favorable immunogenicity and efficacy in patients with solid cancer. A second dose is associated with significantly improved seroconversion, although it is slightly lower in patients with solid cancer compared with healthy individuals.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2026-06-20T03:18:01.777Z","creation":"2025-04-04T19:11:16.335Z"},"accession":"S-EPMC9746490","cross_references":{"pubmed":["36161976"],"doi":["10.1080/21645515.2022.2119763"]}}